The CMA delivered a preliminary judgment in the case last year which concluded that Pfizer and Flynn abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to £50 million the following year.
Pfizer is bearing the brunt of the penalty with a £63 million fine, with Flynn on the hook for £6.7 million.
The pair have been found to have exploited a loophole by de-branding phenytoin sodium capsules – formerly known as Epanutin – so they were no longer subject to price regulations.
